Inference of Tamoxifen's Effects on Prevention of Breast Cancer From a Randomized Controlled TrialSHEN, Yu; QIN, Jing; COSTANTINO, Joseph P et al.Journal of the American Statistical Association. 2007, Vol 102, Num 480, pp 1235-1244, issn 0162-1459, 10 p.Article

Tamoxifen and depression: More evidence from the national Surgical Adjuvant Breast and Bowel project's Breast Cancer Prevention (P-1) randomized studyDAY, Richard; GANZ, Patricia A; COSTANTINO, Joseph P et al.Journal of the National Cancer Institute. 2001, Vol 93, Num 21, pp 1615-1623, issn 0027-8874Article

Tamoxifen Chemoprevention Treatment and Time to First Diagnosis of Estrogen Receptor-Negative Breast CancerYU SHEN; COSTANTINO, Joseph P; JING QIN et al.Journal of the National Cancer Institute. 2008, Vol 100, Num 20, pp 1448-1453, issn 0027-8874, 6 p.Article

Risk of Recurrence and Chemotherapy Benefit for Patients With Node-Negative, Estrogen Receptor-Positive Breast Cancer: Recurrence Score Alone and Integrated With Pathologic and Clinical FactorsGONG TANG; CUZICK, Jack; COSTANTINO, Joseph P et al.Journal of clinical oncology. 2011, Vol 29, Num 33, pp 4365-4372, issn 0732-183X, 8 p.Article

Pathologic variables predictive of breast events in patients with ductal carcinoma in situFISHER, Edwin R; LAND, Stephanie R; SAAD, Reda S et al.American journal of clinical pathology. 2007, Vol 128, Num 1, pp 86-91, issn 0002-9173, 6 p.Article

Effect of factor V leiden and prothrombin G20210h→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trialABRAMSON, Neil; COSTANTINO, Joseph P; GARBER, Judy E et al.Journal of the National Cancer Institute. 2006, Vol 98, Num 13, pp 904-910, issn 0027-8874, 7 p.Article

Lower-category benign breast disease and the risk of invasive breast cancerJIPING WANG; COSTANTINO, Joseph P; TAN-CHIU, Elizabeth et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 8, pp 616-620, issn 0027-8874, 5 p.Article

Effect of tamoxifen on venous thrombosis risk factors in women without cancer: The breast cancer prevention trialCUSHMAN, Mary; COSTANTINO, Joseph P; BOVILL, Edwin G et al.British journal of haematology. 2003, Vol 120, Num 1, pp 109-116, issn 0007-1048, 8 p.Article

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisCORTAZAR, Patricia; LIJUN ZHANG; SWAIN, Sandra M et al.Lancet (British edition). 2014, Vol 384, Num 9938, pp 164-172, issn 0140-6736, 9 p.Article

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1AMIR, Eitan; CECCHINI, Reena S; GANZ, Patricia A et al.Breast cancer research and treatment. 2012, Vol 133, Num 3, pp 1077-1088, issn 0167-6806, 12 p.Article

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20GONG TANG; SHAK, Steven; PAIK, Soonmynng et al.Breast cancer research and treatment. 2011, Vol 127, Num 1, pp 133-142, issn 0167-6806, 10 p.Article

Projecting Individualized Absolute Invasive Breast Cancer Risk in Asian and Pacific Islander American WomenMATSUNO, Rayna K; COSTANTINO, Joseph P; ZIEGLER, Regina G et al.Journal of the National Cancer Institute. 2011, Vol 103, Num 12, pp 951-961, issn 0027-8874, 11 p.Article

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR)RUNOWICZ, Carolyn D; COSTANTINO, Joseph P; WICKERHAM, D. Lawrence et al.American journal of obstetrics and gynecology. 2011, Vol 205, Num 6, pp 535-537, issn 0002-9378, 3 p.Article

Patient-Reported Outcomes in Sentinel Node-Negative Adjuvant Breast Cancer Patients Receiving Sentinel-Node Biopsy or Axillary Dissection: National Surgical Adjuvant Breast and Bowel Project Phase III Protocol B-32LAND, Stephanie R; KOPEC, Jacek A; JULIAN, Thomas B et al.Journal of clinical oncology. 2010, Vol 28, Num 25, pp 3929-3936, issn 0732-183X, 8 p.Article

Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 TrialLAND, Stephanie R; QING LIU; WICKERHAM, D. Lawrence et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 5, pp 823-832, issn 1055-9965, 10 p.Article

The landmark surgical trials of the national surgical adjuvant breast and bowel project : Clinical trials in surgical oncologyLAWRENCE WICKERHAM, D; COSTANTINO, Joseph P; MAMOUNAS, Eleftherios P et al.World journal of surgery. 2006, Vol 30, Num 7, pp 1138-1146, issn 0364-2313, 9 p.Article

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43SIZIOPIKOU, Kalliopi P; ANDERSON, Stewart J; LEASURE, Nick C et al.Breast cancer research and treatment. 2013, Vol 142, Num 2, pp 415-421, issn 0167-6806, 7 p.Article

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical TrialsGOETZ, Matthew P; SCHAID, Daniel J; CARLSON, Erin E et al.Clinical cancer research (Print). 2011, Vol 17, Num 21, pp 6944-6951, issn 1078-0432, 8 p.Article

Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention : American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice GuidelineKRAMER, Barnett S; HAGERTY, Karen L; HARRIS, Russell P et al.Journal of clinical oncology. 2009, Vol 27, Num 9, pp 1502-1516, issn 0732-183X, 15 p.Article

Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen : Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 TrialMAMOUNAS, Eleftherios P; JEONG, Jong-Hyeon; PAJON, Eduardo R et al.Journal of clinical oncology. 2008, Vol 26, Num 12, pp 1965-1971, issn 0732-183X, 7 p.Article

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07LAND, Stephanie R; KOPEC, Jacek A; BEARDEN, James D et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2205-2211, issn 0732-183X, 7 p.Article

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP systemHUDIS, Clifford A; BARLOW, William E; ZUJEWSKI, Jo Anne et al.Journal of clinical oncology. 2007, Vol 25, Num 15, pp 2127-2132, issn 0732-183X, 6 p.Article

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes : The NSABP study of tamoxifen and raloxifene (STAR) P-2 trialVOGEL, Victor G; COSTANTINO, Joseph P; ROBIDOUX, André et al.JAMA, the journal of the American Medical Association. 2006, Vol 295, Num 23, pp 2727-2741, issn 0098-7484, 15 p.Article

Endogenous sex hormones, breast cancer risk, and tamoxifen response : An ancillary study in the NSABP breast cancer prevention trial (P-1)BEATTIE, Mary S; COSTANTINO, Joseph P; CUMMINGS, Steven R et al.Journal of the National Cancer Institute. 2006, Vol 98, Num 2, pp 110-115, issn 0027-8874, 6 p.Article

Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy : Results from five national surgical adjuvant breast and bowel project randomized clinical trialsTAGHIAN, Alphonse G; JEONG, Jong-Hyeon; MAMOUNAS, Eleftherios P et al.Journal of clinical oncology. 2006, Vol 24, Num 24, pp 3927-3932, issn 0732-183X, 6 p.Article